相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
50.0%
尚未招募
1
16.7%
招募中
2
33.3%
暂无批准数据
- Opus Genetics has launched a clinical trial for OPGx-MERTK, an AAV-based gene therapy targeting MERTK-related retinitis pigmentosa, a rare inherited eye disease affecting approximately 60,000 patients worldwide. - The trial will be conducted at Cleveland Clinic Abu Dhabi starting in 2026, funded through Abu Dhabi's Healthcare Research and Innovation Fund, marking the first MERTK gene therapy clinical trial in the UAE. - The investigational therapy delivers a functional copy of the MERTK gene to retinal cells, addressing mutations that impair the retina's ability to recycle photoreceptor components and lead to progressive vision loss. - Currently, there are no approved treatments for MERTK-related retinitis pigmentosa, making this trial the first potential therapeutic opportunity for patients facing inevitable blindness from this condition.
- Medicus Pharma has successfully enrolled 90 patients in its Phase 2 SKNJCT-003 trial evaluating a doxorubicin microneedle array for non-invasive treatment of nodular basal cell carcinoma. - The randomized, double-blind, placebo-controlled study compares two dose levels of the investigational treatment across nine clinical sites in the United States. - Interim analysis from March 2025 showed more than 60% clinical clearance in 26 patients, with topline results expected in Q1 2026. - The company plans to request an end-of-phase 2 meeting with the FDA in the first half of 2026 and estimates a $2 billion potential market opportunity.
- Medicus Pharma Ltd. has received full regulatory and ethical approvals from UK authorities to expand its Phase 2 clinical study SKNJCT-003, evaluating a novel microneedle array treatment for basal cell carcinoma. - The study tests Doxorubicin Microneedle Array (D-MNA) as a non-invasive treatment option, with interim analysis showing over 60% clinical clearance rates in the ongoing 90-patient randomized trial. - The UK expansion enhances global patient recruitment across the United States, Europe, and Middle East, supporting the company's strategy to address what it estimates as a $2 billion market opportunity in BCC treatment.
- Medicus Pharma Ltd. has announced a strategic collaboration with the Gorlin Syndrome Alliance to pursue FDA Expanded Access IND Program for SKINJECT™, targeting patients with multiple, recurrent, or inoperable basal cell carcinomas. - SKINJECT™ is an investigational doxorubicin-containing microneedle array therapy that demonstrated over 60% clinical clearance in interim Phase 2 analysis, offering a non-invasive treatment option for basal cell carcinoma. - Gorlin Syndrome affects approximately 1 in 31,000 people worldwide, with patients developing hundreds to over one thousand basal cell carcinomas throughout their lifetime, creating significant medical and economic burden. - The collaboration aims to establish expanded access framework while collecting real-world safety data and integrating patient community insights into SKINJECT™'s development for this rare disease population.
- The global nanomedicine market is projected to grow from approximately $245 billion in 2023 to over $430 billion by 2028, driven by increasing adoption in oncology, neurology, and regenerative medicine. - Four biotech companies are advancing cutting-edge delivery platforms: Medicus Pharma's microneedle patches for skin cancer, Nanobiotix's radioenhancing nanoparticles, Avidity's antibody-oligonucleotide conjugates for rare diseases, and Arrowhead's multi-tissue RNA interference platform. - These next-generation delivery systems address traditional limitations of oral, intravenous, and subcutaneous administration by improving therapeutic precision, reducing side effects, and enabling targeted drug delivery to previously inaccessible tissues. - Multiple companies have achieved significant clinical milestones, including FDA Fast Track designations, European CE marks, and positive Phase 2 trial results, positioning the sector for potential commercial breakthroughs.
- NeOnc Technologies signed a non-binding term sheet with Quazar Investment for a $50 million equity investment to establish a UAE-based clinical platform focused on the Middle East and North Africa region. - The partnership will create NuroCure, an Abu Dhabi operating subsidiary, to conduct clinical trials for NeOnc's brain cancer therapies NEO100 and NEO212 targeting aggressive cancers like DIPG and glioblastoma multiforme. - The investment will allocate 70% of funds to acquire NeOnc stock at $25 per share and 30% toward launching clinical trials and infrastructure development across the UAE and MENA region. - This marks NeOnc's first international expansion, leveraging Cleveland Clinic Abu Dhabi's FDA-protocol infrastructure and the company's portfolio of over 177 patents worldwide.
- M42, AstraZeneca, and SOPHiA GENETICS announced a strategic collaboration to bring cutting-edge liquid biopsy testing to the UAE, enabling non-invasive genomic profiling through simple blood draws. - The partnership will integrate SOPHiA GENETICS' MSK-ACCESS® technology across select UAE hospitals over 12 months, initially targeting lung, ovarian, breast, colorectal, and pancreatic cancers. - Validation studies will commence at Cleveland Clinic Abu Dhabi with full clinical launch planned for the latter part of Q2 2025, providing faster and less invasive biomarker testing compared to traditional tissue biopsies. - The initiative aims to democratize precision oncology by making advanced diagnostics accessible to patients unable to undergo solid tumor biopsies, supporting personalized treatment matching and real-time disease monitoring.
- The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi becomes the first GCC facility to join a global Phase 3 trial testing a novel SERD anti-estrogen medication for breast cancer recurrence prevention. - The groundbreaking study, funded by AstraZeneca, involves 5,500 participants worldwide and aims to establish a new standard of care by comparing the novel drug against existing hormone therapies. - In the UAE, where breast cancer accounts for 11.6% of annual cancer deaths, this trial represents a significant step toward addressing regional health inequities and advancing cancer treatment options.
